Table 6: Characteristics of study populations at baseline.

Pegaptanib1 0.3 mg ( 𝑛 = 2 9 5 )Pegaptanib1 UC ( 𝑛 = 2 9 6 )Ranibizumab2 ( 𝑛 = 3 7 9 )Ranibizumab2 UC ( 𝑛 = 3 8 1 )

Sex, no(%)
 Male133 (45)120 (40)163 (43)143 (38)
 Female164 (55)178 (60)217 (57)238 (62)

Race, no(%)
 White283 (96)284 (95)268 (97)371 (97)
 Other12 (4)14 (5)12 (3)10 (3)

Age, no(%)
 50–6419 (6)21 (7)30 (8)19 (5)
 65–7486 (29)94 (32)104 (27)102 (27)
 75–84155 (53)160 (54)188 (50)206 (54)
8535 (12)23 (8)57 (15)54 (14)
 Mean76.677.3
 Range52–9353–95

LC, no(%)
 PC72 (24)76 (26)135 (36)141 (37)
 MC111 (38)102 (34)96 (25)89 (23)
 OC112 (38)120 (40)149 (39)151 (40)

Mean LS3.74.23.53.5
ETDRS VAMean56.252.751.350.6
20/20045 (15)45 (15)63 (17)78 (20)
2 0 / 4 0 > V A > 2 0 / 2 0 0 222 (76)221 (75)274 (72)267 (71)
20/4027 (9)30 (10)42 (11)39 (9)

1From VISION Study [6] of pegaptanib, and safety and efficacy summaries provided by Pfizer Inc.
2Pooled estimates from MARINA and ANCHOR [7, 8] studies of ranibizumab.
UC: usual care; LC: lesion composition; PC: predominantly classic; MC: minimally classic; OC: occult with no classic; LS: lesion size; ETDRS VA: early Treatment of Diabetic Retinopathy Study visual acuity.